Indomethacin/prochlorperazine/caffeine: A Review of its use in the acute treatment of migraine and in the treatment of episodic tension-type headache

CNS Drugs

Volumn 25, Issue 4, 2011, Pages 343-358

  Hoy, Sheridan M ^a   Scott, Lesley J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Evaluations; Analgesics, general; Antimigraines, general; Caffeine, general; Indometacin, general; Migraine; Prochlorperazine, general; Tension type headache

Indexed keywords

1 METHYLURIC ACID; 1 METHYLXANTHINE; ACETIC ACID; ACETYLSALICYLIC ACID; ANTIMIGRAINE AGENT; DICLOFENAC; DIFMETRE; DIGOXIN; DOMPERIDONE; ERGOTAMINE; IBUPROFEN; INDOMETHACIN PLUS PROCHLORPERAZINE PLUS CAFFEINE; KAINIC ACID; LITHIUM; METOCLOPRAMIDE; MORPHINE; N METHYL DEXTRO ASPARTIC ACID; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; SUMATRIPTAN; THEOPHYLLINE; TRIPTAN DERIVATIVE; UNCLASSIFIED DRUG;

ABDOMINAL CONSTRICTION; ABDOMINAL DISCOMFORT; ANTINOCICEPTION; AREA UNDER THE CURVE; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COATING; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SELF ADMINISTRATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMBRYO DEVELOPMENT; ENCAPSULATION; EPISODIC TENSION HEADACHE; FETUS DEVELOPMENT; HUMAN; HYPERALGESIA; IN VIVO STUDY; MAJOR CLINICAL STUDY; MAXIMUM PLASMA CONCENTRATION; MIGRAINE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NONHUMAN; PREGNANCY; PRENATAL EXPOSURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RELAPSE; SOMNOLENCE; SUPPOSITORY; TABLET; TACHYCARDIA; THIRD TRIMESTER PREGNANCY; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TREATMENT RESPONSE; TREMOR; URINARY EXCRETION; VERTIGO; VISUAL ANALOG SCALE;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIEMETICS; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; DRUG COMBINATIONS; FEMALE; HUMANS; INDOMETHACIN; MALE; MIDDLE AGED; MIGRAINE DISORDERS; PROCHLORPERAZINE; TENSION-TYPE HEADACHE; YOUNG ADULT;

EID: 79952921870     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11206740-000000000-00000     Document Type: Article

References (36)

1. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004; 24 Suppl. 1: 9-160.
2. Goadsby PJ, Lipton RB, Ferrari MD. Migraine: current understanding and treatment. N Engl J Med 2002 Jan; 346 (4): 257-70.
3. Mett A, Tfelt-Hansen P. Acute migraine therapy: recent evidence from randomized comparative trials. Curr Opin Neurol 2008 Jun; 21 (3): 331-7. (Pubitemid 351653984)
4. Bendtsen L, Evers S, Linde M, et al. EFNS guideline on the treatment of tension-type headache: report of an EFNS task force. Eur J Neurol 2010 Nov; 17 (11): 1318-25.
5. Evers S, A ́ fra J, Frese A, et al. EFNS guideline on the drug treatment of migraine: revised report of an EFNS task force. Eur J Neurol 2009 Sep; 16 (9): 968-81.
6. Stovner LJ, Tronvik E, Hagen K. New drugs for migraine. J Headache Pain 2009 Dec; 10 (6): 395-406.
7. Abbott Products S.p.A. Difmetré (indomethacin/prochlorperazine/ caffeine): summary of product characteristics. Grugliasco: Abbott Products S.p.A., 2010.
8. De Leval X, Dogné J-M, Neven P, et al. Effects of nimesulide and indometacin on COX-1 and COX-2: a comparative study. J Pharm Belg 1999 May-Jun; 54 (3): 89-90. (Pubitemid 29505937)
9. Jacob M, Bjarnason I, Rafi S, et al. A study of the effects of indometacin on liver mitochondria from rats, mice and humans. Aliment Pharmacol Ther 2001 Nov; 15 (11): 1837-42. (Pubitemid 33001148)
10. Hu X-H, Tang H-W, Li Q-S, et al. Central mechanism of indomethacin analgesia. Eur J Pharmacol 1994 Sep; 263 (1-2): 53-7. (Pubitemid 24290252)
11. Galeotti N, Ghelardini C, Grazioli I, et al. Indomethacin, caffeine and prochlorperazine alone and combined revert hyperalgesia in in vivo models of migraine. Pharmacol Res 2002 Sep; 46 (3): 245-50. (Pubitemid 35300763)
12. Ghelardini C, Galeotti N, Grazioli I, et al. Indomethacin, alone and combined with prochlorperazine and caffeine, but not sumatriptan, abolishes peripheral and central sensitization in in vivo models of migraine. J Pain 2004 Oct; 5 (8): 413-9. (Pubitemid 40292180)
13. Jakubowski M, Levy D, Goor-Aryeh I, et al. Terminating migraine with allodynia and ongoing central sensitization using parenteral administration of COX1/COX2 inhibitors. Headache 2005 Jul-Aug; 45 (7): 850-61. (Pubitemid 41045361)
14. Ghelardini C, Galeotti N, Uslenghi C, et al. Prochlorperazine induces central antinociception mediated by the muscarinic system. Pharmacol Res 2004 Sep; 50 (3): 351-8. (Pubitemid 38844491)
15. Ghelardini C, Galeotti N, Bartolini A. Caffeine induces central cholinergic analgesia. Naunyn Schmiedeberg's Arch Pharmacol 1997 Nov; 356 (5): 590-5. (Pubitemid 27478961)
16. Ferná ndez-Tomé MC, Sterin-Speziale NB. Short- and longterm treatment with indometacin causes renal phospholipid alteration: a possible explanation for indometacin nephrotoxicity. Pharmacology, 1994, Jun, 48, 6, 341-8. (Pubitemid 24132887)
17. Buzzi MG, Sakas DE, Moskowitz MA. Indomethacin and acetylsalicylic acid block neurogenic plasma protein extravasation in rat dura mater. Eur J Pharmacol 1989 Jun; 165 (2-3): 251-8. (Pubitemid 19181793)
18. Kamran S, Usmani SS, Wapnir RA, et al. In vitro effect of indomethacin on polymorphonuclear leukocyte function in preterm infants. Pediatr Res 1993 Jan; 33 (1): 32-5. (Pubitemid 23094122)
19. Mathew RJ, Wilson WH. Caffeine consumption, withdrawal and cerebral blood flow.Headache 1985 Sep; 25 (6): 305-9. (Pubitemid 15242395)
20. Rasmussen M. Treatment of elevated intracranial pressure with indomethacin: friend or foe? Acta Anaesthesiol Scand 2005 Mar; 49 (3): 341-50. (Pubitemid 40432528)
21. Zhang W-Y. A benefit-risk assessment of caffeine as an analgesic adjuvant. Drug Saf 2001; 24 (15): 1127-42. (Pubitemid 34151346)
22. Laska EM, Sunshine A, Mueller F, et al. Caffeine as an analgesic adjuvant. JAMA 1984 Apr; 251 (13): 1711-8. (Pubitemid 14174176)
23. Galeotti N, Ghelardini C, ZoppiM, et al. Hypofunctionality of Gi proteins as aetiopathogenic mechanism for migraine and cluster headache. Cephalalgia 2001 Feb; 21 (1): 38-45. (Pubitemid 32304299)
24. Ghelardini C, Galeotti N, Vivoli E, et al. The central analgesia induced by antimigraine drugs is independent from Gi proteins: superiority of a fixed combination of indomethacin, prochlorperazine and caffeine, compared to sumatriptan, in an in vivo model. J Headache Pain 2009 Dec; 10 (6): 435-40.
25. Ferrari A, Savino G, Gallesi D, et al. Effect of overuse of the antimigraine combination of indomethacin, prochlorperazine and caffeine (IPC) on the disposition of its components in chronic headache patients. Pharmacol Res 2006 Aug; 54 (2): 142-9. (Pubitemid 44056237)
26. Isah AO, Rawlins MD, Bateman DN. Clinical pharmacology of prochlorperazine in healthy young males. Br J Clin Pharmacol 1991 Dec; 32 (6): 677-84.
27. Sandrini G, Cerbo R, Del Bene E, et al. Efficacy of dosing and re-dosing of two oral fixed combinations of indomethacin, prochlorperazine and caffeine compared with oral sumatriptan in the acute treatment of multiple migraine attacks: a double-blind, double-dummy, randomised, parallel group, multicentre study. Int J Clin Pract 2007 Aug; 61 (8): 1256-69. (Pubitemid 47052374)
28. Di Monda V, NicolodiM, Aloisio A, et al. Efficacy of a fixed combination of indomethacin, prochlorperazine, and caffeine versus sumatriptan in acute treatment of multiple migraine attacks: a multicenter, randomized, crossover trial. Headache 2003 Sep; 43 (8): 835-44. (Pubitemid 37108340)
29. Cerbo R, Centonze V, Grazioli I, et al. Efficacy of a fixed combination of indomethacin, prochlorperazine, and caffeine in the treatment of episodic tension-type headache: a double-blind, randomized, nimesulide-controlled, parallel group, multicentre trial. Eur J Neurol 2005 Oct; 12 (10): 759-67. (Pubitemid 41495132)
30. Millea PJ, Brodie JJ. Tension-type headache. Am Fam Physician 2002 Sep; 66 (5): 797-804.
31. Taylor FR. Acute treatment of migraine headaches. Semin Neurol 2010 Apr; 30 (2): 145-53.
32. Friedman BW, Grosberg BM. Diagnosis and management of the primary headache disorders in the emergency department setting. Emerg Med Clin North Am 2009 Feb; 27 (1): 71-87.
33. Khoury CK, Couch JR. Sumatriptan-naproxen fixed combination for acute treatment of migraine: a critical appraisal. Drug Des Devel Ther 2010; 4: 9-17.
34. Bendtsen L, Bigal ME, Cerbo R, et al. Guidelines for controlled trials of drugs in tension-type headache: second edition. Cephalalgia 2010 Jan; 30 (1): 1-16.
35. Matchar DB, Young WB, Rosenberg JH, et al. Evidencebased guidelines for migraine headache in the primary care setting: pharmacological management of acute attacks [online]. Available from URL: http://www.aan.com/ professionals/practice/pdfs/gl0087.pdf [Accessed 2010 Nov 3].
36. GlaxoSmithKline. Imitrex- (sumatriptan succinate) tablets: prescribing information [online]. Available from URL: http://www.accessdata.fda.gov/ drugsatfda-docs/ label/2010/020132s013s020s021s022lbl.pdf [Accessed 2011 Jan 24]